Hua seals $111m IPO as retail investors squirm
Hua Medicine, the third biotechnology firm to list in Hong Kong, got across the finish line with an undersubscribed retail book, even though several blue-chip funds threw their weight behind the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: